Interleukin 6 blockade: Tocilizumab in psoriatic arthritis

Fabiola Atzeni, Donatella Ventura, Alberto Batticciotto, Laura Boccassini, Piercarlo Sarzi-Puttini

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy of unknown etiology that is associated with psoriasis. Joint destruction is often progressive: almost half of the patients attending an early arthritis clinic showed radiological damage 2 years after diagnosis. Proinflammatory cytokines are major mediators of systemic and local inflammation, and high levels of interleukin 1 (IL-1), IL-6, and tumor necrosis factor have been found in psoriatic skin lesions and the synovial tissue of patients with rheumatoid arthritis and PsA. IL-6 is a pleiotropic cytokine that mainly signals by membrane (neutrophil and lymphocyte) or soluble (endothelial cell) IL-6 receptors. IL-6 was originally identified as a factor in B cell differentiation, but is now known to influence T cell development: in the presence of IL-6 and transforming growth factor-β (TGF-β), naive T cells develop into Th17 cells, which are important mediators in PsA. IL-6 may also directly contribute to the epidermal hyperplasia seen in psoriatic epithelium and affect the function of dermal inflammatory cells. However, there are no data concerning the use of tocilizumab in patients with PsA, although a pilot study is currently being carried out because the role of IL-6 in the pathogenesis of PsA supports the idea that targeted treatments against IL-6 might be effective. The Journal of Rheumatology

Original languageEnglish
Pages (from-to)97-99
Number of pages3
JournalJournal of Rheumatology
Volume39
Issue numberSUPPL. 89
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Psoriatic Arthritis
Interleukin-6
Cytokines
T-Lymphocytes
Interleukin-6 Receptors
Th17 Cells
Skin
tocilizumab
Joint Diseases
Rheumatology
Transforming Growth Factors
Interleukin-1
Psoriasis
Arthritis
Hyperplasia
Rheumatoid Arthritis
Neutrophils
Epithelium
Endothelial Cells
Tumor Necrosis Factor-alpha

Keywords

  • Inflammatory disease
  • Interleukin 6
  • Psoriasis
  • Psoriatic arthritis
  • Tocilizumab

ASJC Scopus subject areas

  • Immunology
  • Medicine(all)
  • Immunology and Allergy
  • Rheumatology

Cite this

Atzeni, F., Ventura, D., Batticciotto, A., Boccassini, L., & Sarzi-Puttini, P. (2012). Interleukin 6 blockade: Tocilizumab in psoriatic arthritis. Journal of Rheumatology, 39(SUPPL. 89), 97-99. https://doi.org/10.3899/jrheum.120256

Interleukin 6 blockade : Tocilizumab in psoriatic arthritis. / Atzeni, Fabiola; Ventura, Donatella; Batticciotto, Alberto; Boccassini, Laura; Sarzi-Puttini, Piercarlo.

In: Journal of Rheumatology, Vol. 39, No. SUPPL. 89, 07.2012, p. 97-99.

Research output: Contribution to journalArticle

Atzeni, F, Ventura, D, Batticciotto, A, Boccassini, L & Sarzi-Puttini, P 2012, 'Interleukin 6 blockade: Tocilizumab in psoriatic arthritis', Journal of Rheumatology, vol. 39, no. SUPPL. 89, pp. 97-99. https://doi.org/10.3899/jrheum.120256
Atzeni F, Ventura D, Batticciotto A, Boccassini L, Sarzi-Puttini P. Interleukin 6 blockade: Tocilizumab in psoriatic arthritis. Journal of Rheumatology. 2012 Jul;39(SUPPL. 89):97-99. https://doi.org/10.3899/jrheum.120256
Atzeni, Fabiola ; Ventura, Donatella ; Batticciotto, Alberto ; Boccassini, Laura ; Sarzi-Puttini, Piercarlo. / Interleukin 6 blockade : Tocilizumab in psoriatic arthritis. In: Journal of Rheumatology. 2012 ; Vol. 39, No. SUPPL. 89. pp. 97-99.
@article{87004277f1f54f789d99beee01c78675,
title = "Interleukin 6 blockade: Tocilizumab in psoriatic arthritis",
abstract = "Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy of unknown etiology that is associated with psoriasis. Joint destruction is often progressive: almost half of the patients attending an early arthritis clinic showed radiological damage 2 years after diagnosis. Proinflammatory cytokines are major mediators of systemic and local inflammation, and high levels of interleukin 1 (IL-1), IL-6, and tumor necrosis factor have been found in psoriatic skin lesions and the synovial tissue of patients with rheumatoid arthritis and PsA. IL-6 is a pleiotropic cytokine that mainly signals by membrane (neutrophil and lymphocyte) or soluble (endothelial cell) IL-6 receptors. IL-6 was originally identified as a factor in B cell differentiation, but is now known to influence T cell development: in the presence of IL-6 and transforming growth factor-β (TGF-β), naive T cells develop into Th17 cells, which are important mediators in PsA. IL-6 may also directly contribute to the epidermal hyperplasia seen in psoriatic epithelium and affect the function of dermal inflammatory cells. However, there are no data concerning the use of tocilizumab in patients with PsA, although a pilot study is currently being carried out because the role of IL-6 in the pathogenesis of PsA supports the idea that targeted treatments against IL-6 might be effective. The Journal of Rheumatology",
keywords = "Inflammatory disease, Interleukin 6, Psoriasis, Psoriatic arthritis, Tocilizumab",
author = "Fabiola Atzeni and Donatella Ventura and Alberto Batticciotto and Laura Boccassini and Piercarlo Sarzi-Puttini",
year = "2012",
month = "7",
doi = "10.3899/jrheum.120256",
language = "English",
volume = "39",
pages = "97--99",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "SUPPL. 89",

}

TY - JOUR

T1 - Interleukin 6 blockade

T2 - Tocilizumab in psoriatic arthritis

AU - Atzeni, Fabiola

AU - Ventura, Donatella

AU - Batticciotto, Alberto

AU - Boccassini, Laura

AU - Sarzi-Puttini, Piercarlo

PY - 2012/7

Y1 - 2012/7

N2 - Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy of unknown etiology that is associated with psoriasis. Joint destruction is often progressive: almost half of the patients attending an early arthritis clinic showed radiological damage 2 years after diagnosis. Proinflammatory cytokines are major mediators of systemic and local inflammation, and high levels of interleukin 1 (IL-1), IL-6, and tumor necrosis factor have been found in psoriatic skin lesions and the synovial tissue of patients with rheumatoid arthritis and PsA. IL-6 is a pleiotropic cytokine that mainly signals by membrane (neutrophil and lymphocyte) or soluble (endothelial cell) IL-6 receptors. IL-6 was originally identified as a factor in B cell differentiation, but is now known to influence T cell development: in the presence of IL-6 and transforming growth factor-β (TGF-β), naive T cells develop into Th17 cells, which are important mediators in PsA. IL-6 may also directly contribute to the epidermal hyperplasia seen in psoriatic epithelium and affect the function of dermal inflammatory cells. However, there are no data concerning the use of tocilizumab in patients with PsA, although a pilot study is currently being carried out because the role of IL-6 in the pathogenesis of PsA supports the idea that targeted treatments against IL-6 might be effective. The Journal of Rheumatology

AB - Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy of unknown etiology that is associated with psoriasis. Joint destruction is often progressive: almost half of the patients attending an early arthritis clinic showed radiological damage 2 years after diagnosis. Proinflammatory cytokines are major mediators of systemic and local inflammation, and high levels of interleukin 1 (IL-1), IL-6, and tumor necrosis factor have been found in psoriatic skin lesions and the synovial tissue of patients with rheumatoid arthritis and PsA. IL-6 is a pleiotropic cytokine that mainly signals by membrane (neutrophil and lymphocyte) or soluble (endothelial cell) IL-6 receptors. IL-6 was originally identified as a factor in B cell differentiation, but is now known to influence T cell development: in the presence of IL-6 and transforming growth factor-β (TGF-β), naive T cells develop into Th17 cells, which are important mediators in PsA. IL-6 may also directly contribute to the epidermal hyperplasia seen in psoriatic epithelium and affect the function of dermal inflammatory cells. However, there are no data concerning the use of tocilizumab in patients with PsA, although a pilot study is currently being carried out because the role of IL-6 in the pathogenesis of PsA supports the idea that targeted treatments against IL-6 might be effective. The Journal of Rheumatology

KW - Inflammatory disease

KW - Interleukin 6

KW - Psoriasis

KW - Psoriatic arthritis

KW - Tocilizumab

UR - http://www.scopus.com/inward/record.url?scp=84864404652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864404652&partnerID=8YFLogxK

U2 - 10.3899/jrheum.120256

DO - 10.3899/jrheum.120256

M3 - Article

C2 - 22751605

AN - SCOPUS:84864404652

VL - 39

SP - 97

EP - 99

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - SUPPL. 89

ER -